Press releases

November 16, 2023

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

Reveal more

November 1, 2023

Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2^nd Annual Dark Genome Symposium

Reveal more

October 4, 2023

ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer

Reveal more

September 12, 2023

ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease

Reveal more

March 9, 2023

ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development

Reveal more

November 10, 2022

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

Reveal more

November 2, 2022

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

Reveal more

July 18, 2022

ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors

Reveal more

June 30, 2022

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

Reveal more

April 26, 2022

ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy

Reveal more

November 8, 2021

ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models

Reveal more

September 14, 2021

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

Reveal more

July 19, 2021

ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery

Reveal more

March 1, 2021

ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.

Reveal more

September 28, 2020

ROME Therapeutics announces that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies

Reveal more

August 19, 2020

ROME Therapeutics Appoints Drug Discovery Veteran Dennis Zaller, Ph.D., as Chief Scientific Officer

Reveal more

April 27, 2020

ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome

Reveal more

Less

News and events

November 13, 2023

Enara Bio, ROME Therapeutics and Nucleome Therapeutics Host 2nd Annual Dark Genome Symposium

Reveal more

October 12, 2023

ROME honored in BostInno 2023 Fire Awards | BostInno

Reveal more

September 12, 2023

With latest fundraise, Rome Therapeutics works to drug the ‘dark genome’ | BioPharma Dive

Reveal more

September 12, 2023

Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma | Endpoints News

Reveal more

August 4, 2023

"Biotech in Boston" Event Featuring Rosana Kapeller, ROME CEO | Boston Business Journal

Reveal more

June 14, 2023

Rosana Kapeller Among "Disruptors" Featured on WMIF Panel | World Medical Innovation Forum

Reveal more

June 8, 2023

Panel: Maximizing Platform Potential, with ROME CSO Dennis Zaller | Longwood Healthcare Leaders Conference

Reveal more

June 7, 2023

BIO Panel on Oncology Drug Discovery Features ROME CSO Dennis Zaller | BIO International Convention

Reveal more

May 10, 2023

Panel: Building Strong Relationships with Boards and Investors, featuring Rosana Kapeller | Convergence Forum

Reveal more

March 1, 2023

Jumping Genes’ Role in Cancer | The Scientist

Reveal more

November 11, 2022

Podcast: Harnessing the Power of the Repeatome with Dennis Zaller | Biotech2050 podcast

Reveal more

October 7, 2022

ROME CEO Rosana Kapeller Named to Forbes "50 Over 50" | Forbes

Reveal more

September 22, 2022

ROME honored in Endpoints 11: The top private biotechs in pursuit of new drugs | Endpoints News

Reveal more

May 3, 2022

The Mysterious Dark Genome: Panel Featuring Rosana Kapeller, CEO of ROME | World Medical Innovation Forum

Reveal more

March 8, 2022

The "Dark Genome" with Dr. Rosana Kapeller-Lieberman | GV "Theory and Practice" podcast

Reveal more

November 21, 2021

ROME Among C&EN’s 2021 10 Start-Ups to Watch | C&EN

Reveal more

September 14, 2021

Kapeller's ROME bags $77M to strike gold in the backwaters of the genome | Fierce Biotech

Reveal more

September 28, 2020

ROME Named to Fierce Biotech's 2020 Fierce 15 | Fierce Biotech

Reveal more

September 10, 2020

Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry | MassBio

Reveal more

August 20, 2020

Rome snags Merck, Celgene vet Zaller as new CSO | Fierce Biotech

Reveal more

August 20, 2020

ROME founder Rosana Kapeller recruits a CSO from the senior ranks of a major league R&D team | Endpoints News

Reveal more

August 17, 2020

Companies Strain to Outdo Each Other with Work-from-Home Perks (Think Ukuleles) | Wall Street Journal

Reveal more

August 11, 2020

From Rio to Rome: Rosanna Kapeller on The Long Run | The Timmerman Report

Reveal more

April 29, 2020

ROME: Tackling repeat DNA for cancer, autoimmunity | BioCentury

Reveal more

April 28, 2020

At ROME Therapeutics, Kapeller Aims to Turn “Junk” Into New Drugs | Xconomy

Reveal more

April 27, 2020

The Road to ROME's Series A | GV

Reveal more

April 27, 2020

ROME Therapeutics launches to probe junk DNA for cancer drug discovery | C&EN

Reveal more

April 27, 2020

ROME Therapeutics debuts with $50M and Rosana Kapeller at the helm | Fierce Biotech

Reveal more

April 27, 2020

GV joins $50 million round in ROME Therapeutics to research ‘junk DNA’ for cancer therapies | VentureBeat

Reveal more

April 27, 2020

Nimbus founder Rosana Kapeller has a new company, with $50M and an eye on the ‘repeatome’ | Endpoints News

Reveal more

Less

Scientific presentations

November 15, 2023

Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses | ACR Convergence 2023

Reveal more

November 9, 2023

Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription | EMBO Workshop: The Mobile Genome

Reveal more

May 12, 2023

Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription | bioRxiv

Reveal more

January 11, 2023

ROME Therapeutics company presentation | 41st J.P. Morgan Healthcare Conference

Reveal more

November 14, 2022

LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses | American College of Rheumatology Convergence 2022

Reveal more

June 30, 2022

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K–specific inhibition | PNAS

Reveal more

June 5-9, 2022

Sensitive Detection of LINE-1 Retrotransposition Across Cancer Uncovers Biological Correlates | The Mobile DNA Conference: Evolution, Diversity, and Impact

Reveal more

June 5-7, 2022

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) displays a lamivudine resistant genotype and phenotype | 4th Symposium of the Canadian Society for Virology

Reveal more

April 20-23, 2022

Human endogenous retrovirus-k (HERV-K) reverse transcriptase (RT) forms an asymmetric homodimer reminiscent of HIV-1 RT | Cold Spring Harbor Laboratory: Fifty Years of Reverse Transcriptase

Reveal more

March 23, 2022

Reverse transcriptase inhibition disrupts repeat element life cycle in colorectal cancer | Cancer Discovery

Reveal more

Less